EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
1-Year Return
7.54%
This Quarter Return
+10.11%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.84B
AUM Growth
+$168M
(+6.3%)
Cap. Flow
+$31.6M
Cap. Flow
% of AUM
1.11%
Top 10 Holdings %
Top 10 Hldgs %
72.46%
Holding
82
New
9
Increased
14
Reduced
8
Closed
12
Top Buys
| 1 |
Galapagos
GLPG
|
$82M |
| 2 |
Arcus Biosciences
RCUS
|
$62.3M |
| 3 |
Protagonist Therapeutics
PTGX
|
$25.6M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$25.2M |
| 5 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$23.1M |
Top Sells
| 1 |
Relay Therapeutics
RLAY
|
$97.8M |
| 2 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$28.9M |
| 3 |
Nurix Therapeutics
NRIX
|
$25.2M |
| 4 |
Kymera Therapeutics
KYMR
|
$25.2M |
| 5 |
Arvinas
ARVN
|
$24.8M |
Sector Composition
| 1 | Healthcare | 97.98% |
| 2 | Financials | 0.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Zentalis Pharmaceuticals
ZNTL
$116M
| – | – |
-200,000
| Closed | -$10.6M |
|
|
KLRS
77
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86M
| – | – |
-19,435
| Closed | -$8.82M |
|
|
SYRS
78
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-100,000
| Closed | -$5.45M |
|
|
NGM
79
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| – | – |
-143,567
| Closed | -$2.83M |
|
|
BCEL
80
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| – | – |
-2,426,685
| Closed | -$20.7M |
|
|
KDNY
81
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-931,650
| Closed | -$13.2M |
|
|
FSTX
82
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| – | – |
-46,000
| Closed | -$395K |
|